Fig. 4

a Flow cytometric gating strategy depicting identification of T (CD3) and B (CD19+) cells among hCD45+ hematopoietic cells in the spleen (left) and tumor (right). b Frequencies of B (CD19+) B cells in each mouse in spleen and tumors. c Gating strategy to detect myeloid cells, defined as CD33+, CD11b + and/or CD11c+, among the hCD45+ cells in bone marrow and tumors. d Frequencies of myeloid cells in each hu-CB-BRGS mouse in bone marrow and tumor. e Representative flow cytometry analysis depicting expression of HLA-DR MHC Class II molecules on hCD45+ myeloid cells in spleen (top) or tumor (bottom). f Frequencies of HLA-DR+ among myeloid cells in the spleen and tumor for each hu-CB-BRGS mouse. Each dot represents data from an individual spleen, bone marrow or tumor from mice receiving either no drug (Vehicle), nivolumab alone (Nivo), RX-5902 alone, or combination of nivolumab and RX-5902 (Combo) treatment. Lines represent arithmetic means. p-value: * < 0.05